Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

NEW YORK, February 03, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded ...

Nuvation Bio (NUVB) announced it has initiated an Expanded Access Program or EAP for taletrectinib in the U.S. for the treatment of patients with locally advanced or metastatic ROS1-positive or ...

SAN FRANCISCO – Nuvation Bio Inc., a pharmaceutical company focused on cancer treatment with a market capitalization of $769 million, announced the departure of Dr. Jerry Wang, CEO of subsidiary ...

H.C. Wainwright raised the firm’s price target on Nuvation Bio (NUVB) to $11 from $10 and keeps a Buy rating on the shares. The firm sees additional upside in taletrectinib. Published first on ...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded ...

Every investor in Nuvation Bio Inc. (NYSE:NUVB) should be aware of the most powerful shareholder groups. With 46% stake, institutions possess the maximum shares in the company. In other words ...

SAN FRANCISCO – Nuvation Bio Inc., a pharmaceutical company focused on cancer treatment with a market capitalization of $769 million, announced the departure of Dr. Jerry Wang, CEO of subsidiary ...

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company ...

NEW YORK - Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company focused on oncology with a market capitalization of $777 million, has launched an Expanded Access Program (EAP) in the United ...